Insider filing
Traded Aug 31 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Aug 5, 2026 · Filed Aug 5, 2026
A Pfizer director paid $999K out of pocket for Pfizer shares. 2 other people at Pfizer bought some too, in the same month. Shares held went up 142% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$998,821
Shares × reported transaction price
$500K–$1M
+141.6%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
3 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
1 day after results of Aug 4, 2026, 90 days before results of Nov 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $25.81 on Aug 5, 2026, 9% above its 52-week low and 10% below its high, after a 4% rise over the previous 30 trading days
52-week range $23.60 (Sep 25, 2025) to $28.55 (Apr 1, 2026), 45% of the way up, from 251 adjusted closes. 30 trading days earlier: $24.72 on Jun 23, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The largest open-market purchase by any PFE insider in filings since 2006. The first open-market purchase by any PFE insider since Feb 2025. Ronald E Blaylock's largest purchase of PFE in their filings since 2020
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.3% | +1.2% | +1.1% |
| 30 days | +6.1% | −0.3% | +6.4% |
| 90 days | +17.5% | −0.2% | +17.8% |
Past results only. Not a forecast.
Insider filing
Traded Aug 31 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Aug 14 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Fund moves
91 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.